Olympus Corporation
Notice Regarding Receipt of Warning Letter from the FDA
Received a Warning Letter from the FDA. A total of 6 sites are subject. Corrective and preventive actions have been implemented, and a response will be submitted to the FDA within 15 business days. There are no restrictions on product sales, recalls, or sales clearances, and the impact on consolidated results is currently unknown.
Key Figures
- Key Figure 1: Unknown (No figures for net sales, profits, etc. are specified in the body)
- Key Figure 2: Unknown
- Key Figure 3: Unknown
AI要約
Risks and Response
Disclosed receipt of a Warning Letter from the FDA. Six sites are subject, and corrective and preventive actions regarding the quality management system and processes have been implemented. Olympus Corporation is working closely with the FDA and plans to submit a response within 15 business days. At this time, the impact on consolidated results is unknown; material developments will be disclosed in a timely manner.
Business Impact and Future Disclosures
This Warning Letter does not restrict product manufacturing, sales, or distribution, nor does it limit requests for recalls or new sales clearances. The company will continue to prioritize patient safety in its response. If there are material developments, they will be disclosed appropriately in accordance with laws and regulations.
Olympus Corporation
Company overview · Stock price · Financial data · All IR
